AP23464

For research use only. Not for therapeutic Use.

  • CAT Number: I002474
  • CAS Number: 845895-51-4
  • Molecular Formula: C26H30N5O2P
  • Molecular Weight: 475.53
  • Purity: ≥95%
Inquiry Now

AP23464(Cat No.:I002474)is an investigational small molecule being developed as a selective inhibitor of the protein kinase CK2 (casein kinase 2). CK2 is involved in regulating various cellular processes, including cell growth, survival, and DNA repair, and its overactivity has been implicated in several cancers. By inhibiting CK2, AP23464 aims to disrupt these cellular processes, potentially reducing tumor growth and improving the effectiveness of other cancer therapies. The compound is currently undergoing preclinical and early-stage clinical trials to evaluate its safety, pharmacokinetics, and therapeutic potential, particularly in oncology.


Catalog Number I002474
CAS Number 845895-51-4
Synonyms

AP23464; AP-23464; AP 23464;(4-((2-cyclopentyl-9-(3-hydroxyphenethyl)-9H-purin-6-yl)amino)phenyl)dimethylphosphine oxide

Molecular Formula C26H30N5O2P
Purity ≥95%
Solubility Soluble in DMSO, not in water
Storage 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
IUPAC Name 3-[2-[2-cyclopentyl-6-(4-dimethylphosphorylanilino)purin-9-yl]ethyl]phenol
InChI InChI=1S/C26H30N5O2P/c1-34(2,33)22-12-10-20(11-13-22)28-25-23-26(30-24(29-25)19-7-3-4-8-19)31(17-27-23)15-14-18-6-5-9-21(32)16-18/h5-6,9-13,16-17,19,32H,3-4,7-8,14-15H2,1-2H3,(H,28,29,30)
InChIKey VVOYROSONSLQQK-UHFFFAOYSA-N
SMILES CP(=O)(C)C1=CC=C(C=C1)NC2=C3C(=NC(=N2)C4CCCC4)N(C=N3)CCC5=CC(=CC=C5)O
Reference

</br>1:In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW.Blood. 2005 Jul 1;106(1):227-34. Epub 2005 Mar 3. PMID: 15746079 Free Article</br>2:Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. O/’Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15. PMID: 15256422 Free Article

Request a Quote